Clinical trial

#AstraZeneca #Clinical trial #Lupus

AstraZeneca’s lupus treatment shows positive results 

AstraZeneca’s Saphnelo (anifrolumab) has demonstrated strong results for the treatment of systemic lupus erythematosus (SLE).  In the Phase III TULIP-SC trial, 56.2% of patients who received Saphnelo via subcutaneous (SC) self-administration achieved a reduction in disease activity at Week 52 versus 37.1% receiving placebo, as measured by the British Isles Lupus Assessment Group-based Composite Lupus… Read More

#News

Asthma inhaler
#Asthma #Clinical trial

Apogee to advance potential best-in-class asthma treatment 

Biotechnology company Apogee Therapeutics has shared positive data for its potential best-in-class treatment for mild-to-moderate asthma.  Zumilokibart (APG77) was assessed in a Phase Ib double-blind, placebo-controlled trial of 19 adult patients with mild-to-moderate asthma. Results show the treatment was well-tolerated and offered a robust and durable suppression of FeNO, a biomarker… Read More

#News

Breast cancer research
#Breast cancer #Clinical trial #Obesity #Phesi

Breast cancer is world’s most studied disease, report finds 

Breast cancer is the most studied disease globally for a fifth year running, a new report reveals.  Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes,… Read More

#Cancer Research #News

Hepatitis B
#Clinical trial #Genetic medicines #Viral hepatitis

nChroma Bio set to trial chronic hepatitis B virus treatment 

Genetic medicines company nChroma Bio has received a Certificate for Clinical Trial in Hong Kong to start the Phase I/II trial of its treatment for chronic hepatitis B virus (HBV).  CRMA-1001 is an optimised next-generation epigenetic silencer, designed to durably silence HBV antigen expression by methylating both covalently closed circular… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

Blood in a Petri dish
#Clinical trial #CSL #Haemophilia

Results confirm safety and durability of haemophilia drug 

Results from a Phase III trial have confirmed the durability and safety of a one-time infusion to treat adults living with moderate to severe haemophilia B.  Etranacogene dezaparvovec, developed by global biopharma company CSL, was studied in a Phase III open-label, single-dose, single-arm trial, with 54 male participants… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Scientist in laboratory
#ASH 2025 #Clinical trial #Graft vs Host Disease

MaaT013 shows strong survival rate in aGvHD patients 

New results reveal MaaT013 (Xervyteg) achieved a one-year overall survival rate of 54% for the treatment of patients with refractory severe acute Graft-versus-Host Disease (aGvHD).  The data was announced by biotechnology company MaaT Pharma at the American Society of Hematology (ASH) Annual Meeting and Exposition, currently taking place in Orlando, US. Read More

#News

Acute lymphoblastic leukemia
#ASH 2025 #Clinical trial #Leukaemia #Oncology

Pirtobrutinib more effective than ibrutinib, study finds 

A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib).  The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More

#Cancer Research #News

Pills
#Alzheimer's #Clinical trial #Spinogenix

Once-a-day pill could reverse cognitive decline, trial shows 

A new once-a-day pill could reverse cognitive decline in Alzheimer’s patients, a clinical trial has shown.  Tazbentetol, developed by biopharmaceutical company Spinogenix, demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive… Read More

#News

Peanut butter
#Allergen immunotherapy #Allergy #Clinical trial

Immunotherapy could treat nut allergies, results show 

A new immunotherapy could treat patients with nut allergies, preliminary results show.  VLP Peanut, an immunotherapy developed by biotechnology company Allergy Therapeutics, reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated. The treatment was evaluated in 48 patients, with a… Read More

#News

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

Colorectal cancer cells
#Clinical trial #Colorectal cancer #Larkspur Biosciences

First volunteers dosed in colorectal cancer trial 

Biotechnology company Larkspur Biosciences has dosed the first volunteers in the Phase I study of its treatment for microsatellite stable (MSS), colorectal cancer (CRC) and other solid tumours.  LRK-4189 is an oral, first-in-class targeted protein degrader of the lipid kinase PIP4K2C. The drug triggers multiple killing mechanisms… Read More

#News

#AlzeCure Pharma #Alzheimer's #Clinical trial

AlzeCure receives €2.5 million to advance Alzheimer’s drug 

Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment.  AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease in Alzheimer’s.   ACD856… Read More

#Business & Investment #News

Alzheimer's disease drug
#Alzheimer's #Clinical trial #Neurodegenerative disorders

Novel therapeutic could treat neurodegenerative diseases 

A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.  VNA-318, developed by biotechnology company Vandria, was tested in preclinical mouse models of neurodegeneration and cognitive impairment. Data shows the candidate created an immediate improvement in memory, learning and cognitive function, as well… Read More

#News